Venclose Revenue and Competitors

Location

$27M

Total Funding

Estimated Revenue & Valuation

  • Venclose's estimated annual revenue is currently $5M per year.(i)
  • Venclose's estimated revenue per employee is $125,500
  • Venclose's total funding is $27M.

Employee Data

  • Venclose has 40 Employees.(i)
  • Venclose grew their employee count by -18% last year.

Venclose's People

NameTitleEmail/Phone
1
Area VP SalesReveal Email/Phone
2
CFOReveal Email/Phone
3
COOReveal Email/Phone
4
VP Research & DevelopmentReveal Email/Phone
5
SVP, Global Sales & MarketingReveal Email/Phone
6
VP, Sales Europe/Middle EastReveal Email/Phone
7
VP Sales and Marketing EuropeReveal Email/Phone
8
Senior Director Regulatory and Clinical AffairsReveal Email/Phone
9
Director R&D, Product DevelopmentReveal Email/Phone
10
Chief Medical OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$20.3M817%N/AN/A
#2
$8.5M346%N/AN/A
#3
$4.5M18-10%N/AN/A
#4
$8M32-6%N/AN/A
#5
$5.3M210%N/AN/A
#6
$54.2M2169%N/AN/A
#7
$12M48N/AN/AN/A
#8
$10M405%N/AN/A
#9
$30.1M12022%N/AN/A
#10
$14.1M562%N/AN/A
Add Company

What Is Venclose?

We are a medical technology company developing next-generation solutions for the treatment of chronic venous insufficiency, a progressive medical condition affecting an estimated 10% of adults. Our Mission To improve the physician and patient experience during chronic venous insufficiency treatment by commercializing the next-generation RF therapy.

keywords:N/A

$27M

Total Funding

40

Number of Employees

$5M

Revenue (est)

-18%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Venclose News

2020-11-30 - Venclose to Participate in 2020 Piper Sandler Healthcare Conference

SAN JOSE, Calif., Nov. 30, 2020 /PRNewswire/ -- Venclose Inc., a privately-held medical device corporation focused on innovative advancements for the minimally invasive treatment of chronic venous insufficiency, a major underlying cause of varicose veins, today announced that Jerry Gibson, Ven ...

2019-12-04 - Ally Bridge Group Leads Venclose’s $27 Million Series C Funding

SAN JOSE, Calif., Dec. 3, 2019 /PRNewswire/ — Venclose, Inc., a privately-held Silicon Valley medical device company focused on innovative treatment procedures for venous reflux disease, today announced it has closed its Series C funding led by Ally Bridge Group (ABG). ABG is a global life scien ...

2019-12-04 - Venclose closes $27m Series C

Venous reflux disease treatment developer Venclose announced that it closed a Series C funding round totaling $27 million. Venclose develops the next-generation Venclose RF ablation system designed to close damaged veins and restore healthy blood flow in patients with venous reflux disease. Th ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.6M40-9%N/A
#2
$4.6M40-44%N/A
#3
$4.4M4033%$13M
#4
$11.2M40-9%N/A
#5
$7.8M40-5%N/A